Breast Cancer | Specialty

Groundbreaking Breast Cancer Researcher Shares a World of Knowledge

January 14th 2021

Young Hope Rugo saved up her S&H Green Stamps to buy a children’s chemistry set from a Sears catalog. At the age of 8, Rugo knew she wanted to be a scientist.

Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1

January 13th 2021

Palbociclib Fails to Improve PFS in HR+, AI-Resistant Metastatic Breast Cancer

January 12th 2021

January 12, 2021 - Palbociclib in combination with endocrine therapy failed to result in a statistically significant improvement in progression-free survival over capecitabine in patients with hormone receptor–positive metastatic breast cancer who were resistant to aromatase inhibitors.

Practicing Outside the Pharma Box in Breast Cancer

January 9th 2021

Martine J. Piccart discusses her journey into the breast cancer treatment space.

More Innovation Is on Tap for 2021: Five Experts Describe Key Trends

January 8th 2021

The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.

Dr. Hurvitz on the Expanding Metastatic HER2+ Breast Cancer Treatment Arsenal

January 7th 2021

Sara A. Hurvitz, MD, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.

Dr. O'Shaughnessy on the Rationale for the MonarchE Trial in Breast Cancer

January 7th 2021

Joyce A. O'Shaughnessy, MD, discusses the rationale for the monarchE trial in breast cancer.

Updated ExteNET Data Raise Questions Over TKI Utility in HER2+ Breast Cancer With Brain Metastases

January 6th 2021

Adam M. Brufsky, MD, PhD, discusses the updated findings from the ExteNET trial, the role of TKIs in treating patients with brain metastases, and unanswered questions that future research efforts should aim to address.

FDA Grants Fast Track Status to ADC ARX788 for HER2+ Metastatic Breast Cancer

January 5th 2021

January 5th, 2021 -The FDA has granted a fast track designation to the investigational antibody-drug conjugate ARX788 for use as a monotherapy in the treatment of patients with advanced or metastatic HER2-positive breast cancer who have previously received 1 or more HER2-targeted regimens in the metastatic setting.

Novel CDK4/6 Inhibitor ON 123300 Receives Green Light to Move Into Phase 1 Testing in Relapsed/Refractory Advanced Cancers

January 5th 2021

January 5, 2021 – The FDA has granted permission for a phase 1 study evaluating ON 123300, a first-in-class multikinase CDK4/6 inhibitor to proceed under the agent’s investigational new drug application.

Homing in on HER2-Targeted Treatment Strategies in Early and Advanced Breast Cancer

January 5th 2021

Clinical risk continues to guide treatment decisions in early-stage HER2-positive breast cancer. The presence of brain metastases has become a driving force for treatment selection in the metastatic setting.

Parsing Out Remaining Questions With CDK4/6 Inhibitors in HR+ Breast Cancer

January 5th 2021

Sarah Sammons, MD, discusses the clinical significance of ESR1 mutations in HR-positive, HER2-negative breast cancer, how to determine the optimal timing to perform genetic sequencing for ESR1 mutations, and emerging agents, like lasofoxifene, that are poised to transform the paradigm for patients who harbor these mutations.

Boehringer Ingelheim Looks to Expand Targeted Therapies Portfolio

January 5th 2021

January 5, 2020 - Boehringer Ingelheim will add to its cancer cell-directed therapies portfolio with the acquisition of NBE-Therapeutics, the developer of NBE-002, an anti-ROR1 antibody-drug conjugate.

Mobile Intervention for Adherence to Aromatase Inhibitors Misses Mark in Breast Cancer

January 4th 2021

Julie Gralow, MD, discusses exciting research in HER2-positive breast cancer.

Hunt for Predictive Biomarkers for T-DM1 in HER2+ Breast Cancer Continues

January 4th 2021

Ian E. Krop, MD, PhD, highlights the impact of the pivotal KATHERINE trial on the adjuvant treatment of patients with early-stage HER2-positive breast cancer and other recent advances that are moving the needle forward.

O’Shaughnessy Spotlights Key Updates in Triple-Negative Breast Cancer

January 1st 2021

Joyce A. O’Shaughnessy, MD, highlights some of the most exciting updates in triple-negative breast cancer that emerged in 2020.

Matching Novel Targets to Treatment Generates Excitement in TNBC

December 31st 2020

Neelima Vidula, MD, discusses the current and future utility of PARP inhibitors in triple-negative breast cancer, the promise of sacituzumab govitecan, and the need for germline genetic testing.

Pinpointing the Need for Genetic Testing in Oncology

December 31st 2020

Phuong L. Mai, MD, discusses the situations in which genetic testing should be considered and the importance of bridging awareness and access within oncology.

Emergence of Encouraging Biomarkers in TNBC Provide Potential for Personalized Care

December 30th 2020

Debra Patt, MD, highlights recent advancements and novel approaches in triple-negative breast cancer.

Lasofoxifene Emerges as Understanding of ESR1 Mutations Expands in ER+/HER2- Breast Cancer

December 29th 2020

Debu Tripathy, MD, discusses strategies that can be used to overcome ESR1 mutations in estrogen receptor–positive breast cancer.